Eric A. Riesel

Eric A. Riesel

Auto-generated profile, based on publicly available information

Eric A. Riesel

Department of Chemistry

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2018 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MBMehdi Bouhaddou
Mehdi Bouhaddou
ABAnne Marie Barrette
Anne Marie Barrette
ASAlan D. Stern
Alan D. Stern
RKRick J. Koch
Rick J. Koch
MDMatthew S. DiStefano
Matthew S. DiStefano
MBMarc R. Birtwistle
Marc R. Birtwistle
Most cancer cells harbor multiple drivers whose epistasis and interactions with expression context clouds drug and drug combination sensitivity prediction. We constructed a mechanistic computational model that is context-tailored by omics data to capture regulation of stochastic proliferation and death by pan-cancer driver pathways. Simulations and experiments explore how the coordinated dynamics of RAF/MEK/ERK and PI-3K/AKT kinase activities in response to synergistic mitogen or drug combinations control cell fate in a specific cellular context. In this MCF10A cell context, simulations suggest that synergistic ERK and AKT inhibitor-induced death is likely mediated by BIM rather than BAD, which is supported by prior experimental studies. AKT dynamics explain S-phase entry synergy between EGF and insulin, but simulations suggest that stochastic ERK, and not AKT, dynamics seem to drive cell-to-cell proliferation variability, which in simulations is predictable from pre-stimulus fluctuations in C-Raf/B-Raf levels. Simulations suggest MEK alteration negligibly influences transformation, consistent with clinical data. Tailoring the model to an alternate cell expression and mutation context, a glioma cell line, allows prediction of increased sensitivity of cell death to AKT inhibition. Our model mechanistically interprets context-specific landscapes between driver pathways and cell fates, providing a framework for designing more rational cancer combination therapy. Cancer is a complex and diverse disease. Two people with the same cancer type often respond differently to the same treatment. These differences are primarily driven by the fact that two type-matched tumors can possess distinct sets of mutations and gene expression profiles, provoking differential sensitivity to drugs. Over the past few decades, we have seen a shift away from more broadly cytotoxic drugs to more targeted molecules therapies; but how to match a patient with a specific drug or drug cocktail remains a difficult problem. Here, we build a mechanistic ordinary differential equation model describing the interactions between commonly mutated pan-cancer signaling pathways—receptor tyrosine kinases, Ras/RAF/ERK, PI3K/AKT, mTOR, cell cycle, DNA damage, and apoptosis. We develop methods for how to tailor the model to multi-omics data from a specific biological context, devise a novel stochastic algorithm to induce non-genetic cell-to-cell fluctuations in mRNA and protein quantities over time, and train the model against a wealth of biochemical and cell fate data to gain insight into the systems-level, context-specific control of proliferation and death. One day, we hope models of this kind could be tailored to patient-derived tumor mRNA sequencing data and used to prioritize patient-specific drug regimens.

19 September 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EREric A. Riesel
Eric A. Riesel
TMTsach Mackey
Tsach Mackey
HNHamed Nilforoshan
Hamed Nilforoshan
MXMinkai Xu
Minkai Xu
CBCatherine K. Badding
Catherine K. Badding
DFDanna E. Freedman
Danna E. Freedman

16 July 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EREric A. Riesel
Eric A. Riesel
ZFZhenyao Fang
Zhenyao Fang
DFDouglas H. Fabini
Douglas H. Fabini
AAAlison B. Altman
Alison B. Altman
YMYue Meng
Yue Meng
DFDanna E. Freedman
Danna E. Freedman

9 February 2026 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BZBereket L. Zekarias
Bereket L. Zekarias
LGLuis Pablo Arriaga Gonzalez
Luis Pablo Arriaga Gonzalez
OLOlivia A. De Luca
Olivia A. De Luca
AKAndrew Kelly
Andrew Kelly
KQKevin Qian
Kevin Qian
MTMakeda Tekle-Smith
Makeda Tekle-Smith

18 September 2026 in ChemRxiv
Verified
Preprint
Open access
ZJZiyang Jiang
Ziyang Jiang
EREric Riesel
Eric Riesel
INIan Naccarella
Ian Naccarella
TSTaylor D. Sparks
Taylor D. Sparks
The structural and spectroscopic record of a high-throughput synthesis campaign exceeds what experimenters can closely and accurately analyze with conventional tools alone. We report a workflow built for this problem: a language model agent operates an automated Rietveld phasesearch pipeline, Crystalyze Match, built on the open-source DARA engine, and then interprets the phases, optical spectra, and synthesis metadata. We demonstrate this workflow on a 48 sample campaign for the persistent phosphor Ca 2 ZnSi 2 O 7 :Eu 2+ ,Nd 3+ (doped hardystonite), a water-stable candidate alternative to SrAl 2 O 4 :Eu 2+ ,Dy 3+ for luminescent road markings. Within the campaign’s lifetime, the workflow mapped two decomposition pathways, incomplete reaction and zinc volatilization, that validate the two-step synthetic approach. The workflow also identified the fate of the rare-earth dopants: a silicate oxyapatite, Ca 2 (Eu,Nd) 8 (SiO 4 ) 6 O 2 , missed by prior manual analysis, is present in every doped sample. Human adjudication proved necessary as the search first scored the oxyapatite through a lanthanide-free proxy structure that scatters too weakly to register at low fractions, and a corrected-model re-screen of all 48 patterns recovered it. Though the rare-earth dopants appear to end up in the oxyapatite phase, emission rises monotonically with Eu content, and the material shows the target persistent luminescence, so where the emitting Eu 2+ resides remains unresolved. Our work highlights that human review and re-screening after every structure-model revision dramatically improve the trustworthiness of campaign-scale claims.